Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00304811
Recruitment Status : Completed
First Posted : March 20, 2006
Last Update Posted : September 28, 2009
Baylor College of Medicine
Information provided by:
VA Medical Center, Houston

Brief Summary:
The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Condition or disease Intervention/treatment Phase
Staphylococcus Aureus Drug: Vancomycin Drug: Vancomycin plus Gentamicin Drug: Vancomycin plus Rifampin Drug: Vancomycin plus Gentamicin plus Rifampin Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)
Study Start Date : January 2006
Actual Primary Completion Date : January 2007
Actual Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: MRSA

Primary Outcome Measures :
  1. Time to defervescence (24 hours of temperature <100 degrees F)
  2. Return of WBC to normal (<10,500)
  3. negative blood cultures
  4. discharge

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with MRSA in a blood culture processed as standard of care at the VAMC
  • Patients or next of kin willing to sign consent to be randomized by social security number to one of the treatments.

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00304811

United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Medical Center, Houston
Baylor College of Medicine
Principal Investigator: Daniel M Musher, MD Baylor College of Medicine, Houston VA Medical Center Identifier: NCT00304811     History of Changes
Other Study ID Numbers: H-17556
First Posted: March 20, 2006    Key Record Dates
Last Update Posted: September 28, 2009
Last Verified: September 2009

Keywords provided by VA Medical Center, Houston:
Methicillin Resistant Staphylococcus aureus

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Antitubercular Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Protein Synthesis Inhibitors